Decision Support in Massachusetts

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

PASCALL SYSTEMS INC. is a Boston-based medical device company specializing in precision EEG-guided anesthesia management. The company develops a wearable brain monitoring platform that uses advanced signal processing and electroencephalography (EEG) to optimize intraoperative anesthetic administration. The platform aims to reduce unnecessary anesthetic exposure, thereby improving postoperative outcomes and preventing complications such as postoperative delirium (POD) and opioid dependence. The technology integrates real-time physiological data analysis, control engineering, and AI-driven decision support to empower anesthesiologists with personalized, data-driven anesthesia dosing. PASCALL's solution is designed to comply with FDA regulations and operates under rigorous quality management systems. The company focuses on signal extraction, artifact removal, and state-space modeling of brain activity to deliver clinically actionable insights during surgery.

MEDITECH (Medical Information Technology, Inc.) is a privately held healthcare software company founded in 1969, headquartered in Westwood, Massachusetts. The company specializes in developing and supporting integrated electronic health record (EHR) systems and health information technology solutions for healthcare organizations worldwide. MEDITECH serves approximately 2,400 healthcare sites across the United States, Canada, and the United Kingdom, holding a significant share of the U.S. hospital EHR market. The company's flagship product, MEDITECH Expanse, is a web-based EHR platform featuring cloud deployment, mobile access, point-of-care documentation, patient communication tools, and secure patient health portals. MEDITECH is advancing AI-infused EHR solutions to enhance healthcare delivery, improve physician experience, increase operational efficiency, and support predictive analytics and genomics applications. The platform emphasizes data accessibility and interoperability, enabling healthcare leaders to leverage analytics for performance monitoring, clinicians to make data-driven decisions, and patients to benefit from improved care coordination and engagement. MEDITECH maintains partnerships with major technology firms and continues to evolve its services to meet the diverse needs of health systems ranging from large hospital networks to independent community healthcare organizations.

InfoBionic, Inc. is a virtual cardiac telemetry company specializing in AI-enabled remote cardiac monitoring. The company's flagship product, MoMe ARC® (Advanced Remote Cardiology), is recognized as the gold standard in remote cardiac ECG monitoring and represents the first platform to market with hospital-grade continuous monitoring capability deployable from nearly any location. The MoMe ARC® platform integrates advanced artificial intelligence to enhance clinical workflow, detect previously undetected cardiac anomalies, and enable rapid interventions at scale. InfoBionic offers a comprehensive suite comprising MoMe Solutions (AI-enabled ECG analysis), MoMe Sensors (interchangeable, tiered biosensor lead sets configurable for varying acuity levels from high-acuity diagnostics to portable monitoring), and MoMe Analytics™ (business intelligence and AI-embedded analytics for cardiac care operations). The company targets cardiology practices, cardiologists, electrophysiologists, medical leaders, hospital systems, and virtual health programs. InfoBionic has received FDA clearance for its MoMe ARC® Patch (announced August 2025), affirming regulatory compliance and clinical safety. The platform transforms cardiac data into actionable clinical insight through proprietary AI algorithms focused on arrhythmia detection, atrial fibrillation monitoring, and congenital heart disease assessment. Products are designed to improve patient quality of life through earlier interventions, enhance operational efficiency across departments, and support both enterprise and telehealth deployment models.

VUNO Med, Inc. develops AI-driven diagnostic and patient monitoring software solutions for healthcare providers. The company manufactures two principal FDA-cleared products: VUNO Med®-DeepCARS®, an early warning system for cardiac arrest risk assessment in general ward inpatients using vital signs monitoring (heart rate, blood pressure, respiratory rate, oxygen saturation, plus age and timing); and VUNO Med®-Chest X-ray™ Triage, an AI-based diagnostic support system for detecting suspected chest abnormalities and major pulmonary diseases from chest radiography. Both products integrate deep learning algorithms with clinical workflows to assist healthcare professionals in reducing response times, lowering clinical costs, and improving patient outcomes. The DeepCARS system has been prospectively validated in multicentre studies published in peer-reviewed journals including Critical Care Medicine and Resuscitation, demonstrating predictive value for in-hospital cardiac arrest and unplanned ICU transfer. The Chest X-ray Triage system has undergone external validation for detection of nodular and reticular opacities in interstitial lung disease and other pulmonary conditions. VUNO distributes its solutions primarily to hospitals and health systems in the United States and maintains clinical advisory relationships with leading academic medical centers. The company emphasizes regulatory compliance and clinical evidence to support adoption in acute care settings.

Picis Clinical Solutions develops cloud-based and on-premise surgical patient management and clinical information software for hospitals, ambulatory surgery centers (ASCs), and government healthcare facilities. The company specializes in perioperative software systems that integrate device data, enable seamless clinical documentation, and support workflow optimization across the surgical care continuum. Primary product suites include Perioperative Suite (perioperative documentation and patient flow), Clinical Information System Suite (cross-continuum care coordination), Experior ASC (combined clinical and practice management for surgical centers), and Government Suite (VA-integrated scheduling and workflow). Key specialized applications include Anesthesia Manager (device integration and historical data management), SmarTrack Next (perioperative patient tracking and communication), Orchestrator (surgical workflow management), PriorityQ (surgical scheduling optimization), RapidICU (crisis-mode ICU solutions), and Envision Analytics (healthcare business intelligence and revenue cycle analytics). Picis solutions are designed by clinicians for clinicians and emphasize interoperability, data synchronization across the perioperative suite, and decision support. The company serves hospitals, health systems, ASCs, and VA facilities internationally. Training and implementation support are available. Certifications and regulatory status not explicitly stated on homepage but inferred from healthcare software deployment context.

Empatica is a digital health company specializing in FDA-cleared wearable devices and clinical-grade digital biomarker platforms for remote patient monitoring and clinical research. The company develops continuous health monitoring solutions that collect physiological data from everyday life, with particular expertise in neurological applications including epilepsy monitoring and Parkinson's disease assessment. Empatica's Health Monitoring Platform is an end-to-end remote monitoring solution designed for clinical trials, providing raw data collection and validated digital biomarkers across multiple therapeutic areas. The platform features over 300 digital measures derived from wearable sensors, supporting objective monitoring of motor symptoms, seizure detection, and treatment response. Empatica holds 8 FDA clearances and CE MDR certification. The company's wearable devices, including the EmbraceMini and EpiMonitor, are deployed across 160+ countries in over 40 languages. More than half of the top 20 pharmaceutical companies use the Empatica platform for clinical trial monitoring and digital endpoint development. The technology has been referenced in over 12,000 research publications. Empatica serves pharmaceutical companies, contract research organizations, academic medical centers, and healthcare systems requiring objective, continuous health data collection outside traditional clinical settings.

Cumulus Neuroscience develops NeuLogiq®, a medical-grade, at-home digital data collection and analytics platform for functional brain health monitoring and central nervous system (CNS) disease management. The platform combines a 510(k)-cleared novel EEG headset with tablet-based cognitive, mood, language, and sleep assessments, synced to cloud-based machine learning analytics. NeuLogiq enables frequent longitudinal monitoring in clinical and home settings, designed to address challenges in CNS drug discovery including late diagnosis, patient stratification, and treatment monitoring. The company serves pharmaceutical companies conducting clinical trials through its Cumulus Pharma Advisory Group (CPAG), a paid-in consortium that includes ten major global pharmaceutical companies: Biogen, GSK, Pfizer, Eli Lilly, Takeda, Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche, and J&J Innovative Medicine. Several CPAG members have active studies using the NeuLogiq Platform. The platform assesses discrete brain functions including working memory, episodic memory, executive function, decision-making, neuronal integrity, network connectivity, emotional bias, speech characteristics, and sleep metrics. The company employs approximately 30 engineers, scientists, and business professionals, backed by experienced life science and technology investors including the Dementia Discovery Fund, as well as UK and EU innovation agencies. Regulatory clearance includes FDA 510(k) for the EEG headset. NeuLogiq integrates third-party validated algorithms for facial expression recognition, language analysis, and sleep staging.

Linus Health is a digital health company that develops AI-enabled cognitive assessment platforms for early detection and management of cognitive impairment and dementia. The company provides scientifically-validated digital cognitive testing solutions that integrate long-trusted neuropsychological assessments with advanced analytics to deliver actionable clinical insights. Linus Health's platform serves two primary market segments: healthcare delivery (primary care practices, medical centers, specialty neurology) and life sciences (clinical trials, research studies). The technology originated from 8+ years of R&D performed at MIT and Lahey Medical Center. The platform has been validated in over 150 peer-reviewed publications across journals including Neurology, Journal of Alzheimer's Disease, and Neuropsychologia, demonstrating sensitivity in detecting subtle cognitive impairment and associations with Alzheimer's biomarkers. The company targets the significant gap in cognitive care capacity—projected neurologist shortages of 19% by 2025—and the critical window for intervention, as Alzheimer's pathology can present 15-20 years before overt symptoms. Linus Health's digital assessment approach makes cognitive testing more accessible, practical, and efficient compared to traditional in-clinic methods. The platform is designed for integration across care settings and supports earlier detection workflows aligned with emerging biomarker-driven treatment paradigms. The company has received recognition including TIME Magazine Best Inventions and Fast Company Innovation by Design awards.

Sim&Cure is a medical technology company specializing in next-generation brain aneurysm treatment solutions for endovascular procedures. The company develops digital twin and AI-powered software platforms designed to support physicians in neurovascular care. Their flagship product, Sim&Size, is a surgical planning and procedural support system that leverages patient-specific computational modeling to enhance procedural planning and execution for aneurysm treatment. The platform integrates with major medical imaging and device systems from partners including Siemens, Philips, Medtronic, Stryker, MicroVention-Terumo, and others. Sim&Cure's solutions are deployed across multiple continents, serving hospitals and healthcare professionals globally. The company operates through regional product life cycle teams covering EMEA, APAC, and Americas markets. Their regulatory and quality assurance infrastructure is led by senior leadership with expertise in medical device compliance. Sim&Cure has secured significant funding (€10M Series extension as of late 2025) to advance its neurovascular procedure platform. The company positions itself as a research and innovation leader in aneurysm care, collaborating with healthcare systems to improve procedural success rates and patient outcomes through intelligent, data-driven decision support.

Predictive Healthcare, Inc. develops MyHealthPal™, an FDA-listed Class I medical device platform for remote postoperative surgical site infection (SSI) monitoring. The platform uses artificial intelligence and standard consumer smart devices (smartphones) to enable patients to submit wound photos and clinical inputs that feed into an algorithm assessing SSI risk in real time. Clinicians receive predictive risk alerts to guide postoperative decision-making and early intervention. The system integrates with existing electronic medical record (EMR) systems and supports asynchronous postoperative visits, reducing unnecessary in-person wound checks while maintaining vigilant monitoring for patients with geographic or social barriers to care access. MyHealthPal addresses a significant clinical need: approximately 5 in 100 surgeries result in SSI, costing US hospitals $10 billion annually. The company is FDA-registered and operates under a Class I medical device designation. The platform is currently available for sale in the United States only and is positioned for perioperative programs across surgical specialties, with demonstrated interest in orthopedic, spinal, pediatric, and general surgery applications.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.

Etiometry, Inc. is a Boston-based medical technology company specializing in AI-driven clinical decision-support software for intensive care units (ICUs). The Etiometry Platform (T3 Platform) aggregates real-time patient data from bedside monitors, peripheral devices, and EHR systems into a unified dashboard powered by Bayesian models and proprietary AI algorithms. The platform computes personalized risk indices to enable proactive care management in both pediatric and adult critical care settings. Core features include data aggregation and visualization, risk analytics for hemodynamic and respiratory management, automated clinical pathway workflows aligned with hospital protocols, and quality improvement analytics. The platform has received 11 FDA 510(k) clearances and CE marking, and has been deployed across 150+ clinical studies leveraging 150+ million hours of de-identified patient data. Clinical evidence demonstrates up to 36% reduction in length of stay, 41% decrease in ICU readmissions, 30% reduction in mechanical ventilation time, and 29% shorter vasoactive infusion duration. Trusted by leading academic medical centers and top-ranked children's hospitals across North America, Europe, and Asia.

Glytec is a healthcare technology company specializing in intelligent glycemic management software for hospital systems. Founded in 2006, Glytec developed the first FDA-cleared software for glucose management and has since deployed its platform across 400+ hospitals. The flagship offering, GlytecOne, is a unified clinical decision support platform that combines FDA-cleared Glucommander® insulin dosing algorithms with workflow automation, real-time clinical decision support, enterprise analytics, and population health intelligence. The platform integrates seamlessly with electronic health records (EHRs) to deliver personalized, real-time insulin dosing recommendations, standardized clinical workflows, and comprehensive performance analytics aligned with CMS eCQM reporting requirements. Glytec's solutions have demonstrated significant outcomes: 99.8% reduction in inpatient hypoglycemia, 3.1% A1C reduction, 68% reduction in 30-day readmissions, and 6–8x ROI. The platform addresses mandatory CMS glycemic harm eCQM reporting beginning in 2026, helping hospitals strengthen patient safety, optimize clinical workflows, and reduce medication-related adverse events.

PaxeraHealth is a Boston-based enterprise medical imaging software company specializing in AI-driven imaging platforms and solutions. The company develops advanced Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and vendor-neutral archive (VNA) platforms designed for healthcare providers globally. PaxeraHealth's core portfolio includes PaxeraUltimaAI—an AI-assisted enterprise imaging platform with native diagnostic algorithms to enhance workflow efficiency and reporting speed; ARK—a no-code imaging algorithm platform enabling users to develop multimodal AI algorithms without coding expertise; and VNAi—a data warehouse imaging platform providing secure, vendor-neutral control of imaging data with advanced lifecycle management. The company serves over 1,500 healthcare customers across 45 countries, managing 220+ million imaging studies annually. PaxeraHealth's solutions emphasize workflow automation, diagnostic accuracy improvement, clinical decision support, and seamless interoperability with existing EMR and PACS systems. The company employs approximately 106 people from 12 countries and maintains regional offices and a global distributor network to support healthcare systems of all sizes.

Buoy Health is an AI-powered digital health platform that provides symptom assessment, clinical decision support, and care navigation for consumers. The platform combines machine learning algorithms with clinician-reviewed medical content to help users identify potential health conditions based on self-reported symptoms and receive personalized guidance on appropriate care pathways. Founded by physicians and data scientists at Harvard Innovation Labs, Buoy integrates artificial intelligence-driven triage with expert-curated health information, enabling users to make informed decisions about seeking professional medical care. The company serves individuals seeking accessible, evidence-based health guidance and care coordination outside traditional clinical settings.

Neximatic is a medical device connectivity platform that automates vital signs streaming from clinical monitoring equipment directly into electronic health record (EHR) systems. The company offers a plug-and-play hardware and software solution that eliminates manual vital sign charting, improves clinical workflow efficiency, and reduces documentation errors. Neximatic's proprietary device integrates data from over 200 medical devices and supports major EHR platforms including Epic, Cerner, Medidata, and others. The solution has been deployed in over 1,000 healthcare facilities across the United States and internationally, with more than 10,000 units in active use. The platform is engineered for reliability, scalability, and ease of deployment, with minimal maintenance requirements. Beyond real-time vital sign transmission, Neximatic's infrastructure supports clinical decision support engine development and other innovative EHR functionalities, enabling healthcare organizations to enhance patient safety and operational efficiency.

REEV is a medical robotics company specializing in personalized mobility solutions for individuals with neurological gait disorders, including stroke survivors, multiple sclerosis, and paraplegia patients. The company offers an integrated two-product platform: REEV SENSE, an AI-powered wearable gait analysis system that captures real-time kinematic data via dual sensors, and DREEVEN, a motorized knee-ankle-foot orthosis (KAFO) that provides personalized robotic assistance based on patient-specific gait signatures. The system enables certified orthotists and rehabilitation clinics to perform rapid gait calibration, monitor patient progression through mobile analytics, and deliver customized motor control assistance in outpatient and clinical settings. REEV's technology integrates electro-hydraulic actuation with machine learning algorithms to adapt orthotic support dynamically to each patient's walking pattern, improving functional mobility and independence.